| 產(chǎn)品名稱 |
NCI-H889 [H889] |
| 商品貨號(hào) |
B165376 |
| Organism |
Homo sapiens, human |
| Tissue |
lung; derived from metastatic site: lymph node |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
clusters in suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
stage E, carcinoma; classic small cell lung cancer |
| Age |
69 years |
| Gender |
female |
| Ethnicity |
Caucasian |
| Derivation |
This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis taken from a patient prior to therapy. |
| Clinical Data |
female
69 years
Caucasian |
| Comments |
The cells express reduced levels of p53 mRNA compared to levels found in normal lung.
There is a point mutation, a G to C transition (TGC to TCC), which results in a substitution of a serine for cysteine at codon 242.
The cells carry the K-ras 12 mutation. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.
Medium Renewal: Every 2 to 3 days
|
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 10 D13S317: 11 D16S539: 8 D5S818: 12 D7S820: 8,9 THO1: 8,9.3 TPOX: 8,9 vWA: 17 |
| Name of Depositor |
AF Gazdar, JD Minna |
| Deposited As |
Homo sapiens |
| References |
Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
|
